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World thalassemia day is celebrated every year on May 8 to raise the public awareness of the disease. Endocrine abnormalities are among the most common 
complications of β-thalassemia major. The metabolically 
active iron gets deposited in endocrine organs. Timely iron 
chelation can reduce hyperferritinemia, hence, ameliorating the 
endocrinopathies. The May 2019 issue of Indian Journal of Child 
Health is publishing an article by Kataki and Bharati, where authors 
have described the influence of ferritin levels in early detection 
of endocrinopathies among 70 such children aged 5–18 years 
hailing from Northeast India [1]. Existing literature have stressed 
on judicious blood transfusions and serial ferritin measurement 
in recognizing endocrine complications [2]. Pituitary damage 
due to iron overload is the underlying pathogenetic factor in 
hypogonadism and partly contributes to poor growth [3]. Puberty 
is the stage of the maximal growth insult. The current practice 
is to begin iron chelation therapy when the serum ferritin levels 
reach 1000 ng/ml or when child reaches 3 years of age or has 
received about 10–20 transfusions [2].
The strength of this article is the adaptation to the resource-
limited settings. Simple physical parameters such as height and 
sexual maturity rating were used alongside measurement of 
serum ferritin, calcium, alkaline phosphatase, phosphate, thyroid-
stimulating hormone, RBS, and fasting blood sugar. However, 
more workup is required to timely recognize hypogonadism. 
Additional assessment of free T4 levels, gonadotropins 
(luteinizing hormone and follicle-stimulating hormone), and 
bone age (X-ray of wrist and hand) is needed in the ideal scenario 
as per the international network on endocrine complications in 
thalassemia (I-CET) position statement and guideline [4].
It is worthwhile to note that through this article, authors have 
made a valiant effort on measuring ferritin levels which help in 
early control of endocrinopathies in thalassemia. Hypocalcemia, 
due to hypoparathyroidism, is a recognized late complication of 
iron overload and/or anemia. Hence, optimal age of screening 
should begin from the age of 16 years [5]. In cases with low 
serum calcium and high phosphate levels, parathyroid hormone 
and 1, 25-dihydroxycholecalciferol (Vitamin D) should also 
be evaluated. Impaired glucose tolerance and diabetes mellitus 
may be the consequence of β-cell destruction secondary to iron 
overload and chronic liver disease.
Future research should be done utilizing the thalassemia 
registry across the focused clinics across India, so as to capture 
the entire spectrum of hormonal problems. Specific imaging of 
pituitary and gonads also needed in quantifying iron toxicity.
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